KRAS and non-small cell lung carcinoma: These data support a role for miR-16 in overcoming the intrinsic resistance of NSCLC to erlotinib and provide the biological preclinical rationale for a miR-16–erlotinib combination in the treatment of KRAS-mutated NSCLC.